KSQ Therapeutics Announces Leadership and Board Additions

by s2desi5_ksqtherapeutics | Sep 23, 2022 | Uncategorized

Micah Benson, PhD, promoted to Chief Scientific Officer  Tom Leitch joins as Chief Technology Officer  Outgoing CSO Frank Stegmeier, PhD, transitions to board of directors Lexington, Mass., September 23, 2022- KSQ Therapeutics, a clinical-stage biotechnology company...

KSQ Therapeutics Announces First Patient Dosed in Combination Portion of the Ongoing Phase 1 Study of KSQ-4279, A First-In-Class USP1 Inhibitor, In Patients with Advanced Solid Tumors

by s2desi5_ksqtherapeutics | Dec 7, 2022 | Uncategorized

Lexington, Mass., December 7, 2022- KSQ Therapeutics, a clinical-stage biotechnology company developing therapies to treat cancer and autoimmune diseases using its proprietary, integrated discovery CRISPRomics® platform, today announced the initiation of dosing in the...

KSQ Appoints Mahesh Karande to its Board of Directors

by s2desi5_ksqtherapeutics | Dec 8, 2022 | Uncategorized

Lexington, Mass., December 8, 2022 – KSQ Therapeutics, a clinical-stage biotechnology company developing therapies to treat cancer and autoimmune diseases using its proprietary, integrated discovery CRISPRomics® platform, today announced the appointment of Mahesh...

KSQ Therapeutics Announces Ono Pharmaceutical Co., Ltd. is Acquiring Multiple Research-Stage Oncology Programs Identified with KSQ’s CRISPRomics® Platform Technology

by s2desi5_ksqtherapeutics | Jan 25, 2023 | Uncategorized

Lexington, Mass., January 25, 2023 KSQ Therapeutics, a clinical-stage biotechnology company developing therapies to treat cancer and autoimmune diseases using its proprietary, integrated discovery CRISPRomics platform, announced today that Ono Pharmaceutical Co., Ltd....

KSQ Therapeutics Announces First Patient Dosed in Clinical Development Program for KSQ-001EX, a CRISPR/Cas9 Engineered Tumor Infiltrating Lymphocyte (eTIL^®) Therapy

by s2desi5_ksqtherapeutics | Jun 12, 2024 | Uncategorized

Lexington, Mass., June 12, 2024 — KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing treatments for solid tumors, today announced the first patient dosed in the Phase 1/2 clinical study of KSQ-001EX, a novel edited TIL therapy. KSQ-001EX...